Health Canada’s Notice on the Medical Device Single Audit ProgramPublished on January 22, 2018
Author: Pinky Mazumder
Late last year, Health Canada issued a notice to the industry on the reduction of audit times for the Medical Device Single Audit Program (“MDSAP”).
The MDSAP, introduced by the International Medical Devices Regulators Forum in 2012, seeks to harmonize a single audit of medical devices to meet the Quality Management System requirements for more than one regulatory agency. The objective is to reduce regulatory burdens and align the regulatory requirements across various agencies. Previously, manufacturers were required to comply with the Canadian Medical Devices Conformity Assessment System (CMDCAS) and submitted their issued CMDCAS certificates to Health Canada. Per the MDSAP transition program, Health Canada currently accepts both CMDCAS certificates as well as MDSAP certificates, however starting January 1st, 2019, Health Canada will only accept MDSAP certificates.
In the Notice, Health Canada encourages manufacturers to ensure that corresponding Auditing Organizations schedule a transition as soon as practicable. Manufacturers who fail to transition before January 1st, 2019 could face compliance actions and even the cancellation of their medical device licenses. The Notice also mentions that comments were received from license holders which led to the MDSAP Consortium to make the following changes:
- To reduce the overall time required for audit and reduce the number of tasks, the MSDAP audit approached has been streamlined in the revision of the audit model.
- For manufacturers with 45 employees or less, the audit time is to be reduced by 10%
- For manufacturers with 15 employees or less, the audit time is to be reduced by 20%
- The duration of surveillance and re-certification audits are to be reduced by 20% for all manufacturers
- With the purpose to reduce audit time, the expectations for annual surveillance audits have been clarified
Thank you for reading Regulated Affairs, the CAPRA blog. CAPRA is a non-profit organization dedicated to providing professional development opportunities in Regulatory Affairs. Feel free to share our blog posts and join us on social media.
Rare Diseases and Orphan Drugs Regulatory Framework in Canada: Recent Initiatives by Government of Canada
What are Rare Diseases and How do They Affect Canadians? According to Health Canada, rare diseases are life-threatening, debilitating, or serious and chronic conditions that...
Health Canada changes filing requirements for product monographs
Did you know, effective immediately, Health Canada is changing the submission requirements for second language product monographs for human drugs? This is for only post-life...
Pragmatic Clinical Trials: Testing Treatments in the Real-World
What is a Pragmatic Clinical Trial? Clinical trials can be designed to be either pragmatic or explanatory. Explanatory trials are designed to find out whether a treatment...